Lilly's Basaglar Insulin Glargine Will Be US Blockbuster
With second-quarter sales of over $232m in the US, Eli Lilly's Basaglar hybrid insulin glargine is close to becoming a $1bn blockbuster on a proforma annual basis. Global sales of the brand are already tracking well ahead of $1bn.
You may also be interested in...
Against a backdrop of continued outcry over insulin costs in the US and the looming FDA-imposed transition of insulins to biologic status in early 2020, legislators and manufacturers alike are still lobbying for alternative approaches to the essential diabetes treatment.
Immediately upon reimbursement listing, Mylan has launched in Australia the insulin glargine biosimilar that it co-developed with India’s Biocon.
Novo Nordisk will launch US authorized generics of its NovoLog and NovoLog Mix at half the price of the brands from the start of 2020.